carmustine has been researched along with Leukemia, Lymphocytic in 44 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Two doses of carmustine at intervals of one week could eradicate the disease even during the phase of logarithmic growth of the leukaemic cells, this result depending upon the level of treatment and time of dosing post-inoculation with leukaemic cells." | 1.27 | Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia. ( Bock, M; Jackson, H; Jackson, NC; Lendon, M, 1984) |
| "In adult acute lymphocytic leukemia (ALL) cure is rare." | 1.27 | Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission. ( Dicke, KA; Keating, MM; McCredie, KB; Spitzer, G; Vellekoop, L; Verma, DS; Zander, AR, 1984) |
| "Twenty-one patients had malignant lymphomas, three, acute lymphoblastic leukemia (ALL), and two, malignant thymomas." | 1.27 | Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. ( Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ, 1988) |
| "Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia." | 1.26 | Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. ( Canellos, GP; Gralnick, HR; Rosenthal, S; Whang-Peng, J, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (95.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, T | 1 |
| Pashaei, S | 1 |
| Jaffrey, I | 1 |
| Ryder, J | 1 |
| Puig, N | 1 |
| de la Rubia, J | 1 |
| Remigia, MJ | 1 |
| Jarque, I | 1 |
| Martín, G | 1 |
| Cupelli, L | 1 |
| Sanz, GF | 1 |
| Lorenzo, I | 1 |
| Sanz, J | 1 |
| Martínez, JA | 1 |
| Jiménez, C | 1 |
| Sanz, MA | 1 |
| Jackson, H | 1 |
| Jackson, NC | 1 |
| Bock, M | 1 |
| Lendon, M | 1 |
| Takahashi, I | 1 |
| Oda, Y | 1 |
| Lai, M | 1 |
| Fukumoto, M | 1 |
| Nishimura, M | 1 |
| Yorimitsu, S | 1 |
| Kitajima, K | 1 |
| Kimura, I | 1 |
| Vellekoop, L | 1 |
| Dicke, KA | 1 |
| Zander, AR | 1 |
| Spitzer, G | 1 |
| Verma, DS | 1 |
| Keating, MM | 1 |
| McCredie, KB | 1 |
| Rai, KR | 1 |
| Sawitsky, A | 1 |
| Jagathambal, K | 1 |
| Gartenhaus, W | 1 |
| Phillips, E | 2 |
| Stryckmans, PA | 1 |
| Otten, J | 1 |
| Delbeke, MJ | 1 |
| Suciu, S | 2 |
| Fière, D | 1 |
| Bury, J | 2 |
| Solbu, G | 2 |
| Benoit, Y | 1 |
| Kempin, S | 1 |
| Lee, BJ | 1 |
| Thaler, HT | 1 |
| Koziner, B | 1 |
| Hecht, S | 1 |
| Gee, T | 1 |
| Arlin, Z | 1 |
| Little, C | 1 |
| Straus, D | 1 |
| Reich, L | 1 |
| Al-Mondhiry, H | 1 |
| Dowling, M | 1 |
| Mayer, K | 1 |
| Clarkson, B | 1 |
| Sexauer, CL | 1 |
| Vietti, T | 1 |
| Humphrey, GB | 2 |
| Pullen, DJ | 1 |
| Sullivan, MP | 1 |
| Falletta, JM | 1 |
| Boyett, JM | 1 |
| Starling, KA | 1 |
| Land, VJ | 1 |
| Dyment, PG | 1 |
| Vats, T | 1 |
| Duncan, MH | 1 |
| Furusawa, E | 1 |
| Suzuki, N | 1 |
| Furusawa, S | 1 |
| Lee, JY | 1 |
| Rosenthal, S | 1 |
| Canellos, GP | 1 |
| Whang-Peng, J | 1 |
| Gralnick, HR | 1 |
| Kung, FH | 1 |
| Nythan, WL | 1 |
| Cuttner, J | 1 |
| Falkson, G | 1 |
| Lanzkowsky, P | 1 |
| Del Duca, V | 1 |
| Nawabi, IU | 1 |
| Koch, K | 1 |
| Pluess, H | 1 |
| Freeman, A | 1 |
| Burgert, EO | 1 |
| Leone, LA | 1 |
| Ruymann, F | 1 |
| Patterson, RB | 1 |
| Degnan, T | 1 |
| Hakami, N | 1 |
| Pajak, TF | 1 |
| Holland, J | 1 |
| Murphy, SG | 1 |
| LoBuglio, AF | 1 |
| Bender-Gotze, C | 1 |
| Albert, ED | 1 |
| Wundisch, GF | 1 |
| Kolb, HJ | 1 |
| Thiel, E | 1 |
| Grosse-Wilde, H | 1 |
| Lieven, HV | 1 |
| Hemsworth, GR | 1 |
| Wolff, JS | 1 |
| Kraska, AR | 1 |
| Jensen, KE | 1 |
| Medoff, G | 2 |
| Valeriote, F | 2 |
| Ryan, J | 1 |
| Tolen, S | 1 |
| Goldenberg, GJ | 1 |
| Clarkson, BD | 4 |
| Dowling, MD | 3 |
| Gee, TS | 3 |
| Cunningham, IB | 1 |
| Burchenal, JH | 5 |
| Haghbin, M | 3 |
| Cunningham, I | 1 |
| Middleman, MP | 1 |
| Jochimsen, PR | 1 |
| Pearlman, NW | 1 |
| Lawton, RL | 1 |
| Lynch, RG | 1 |
| Gaspard, MH | 1 |
| Maraninchi, D | 2 |
| Stoppa, AM | 1 |
| Gastaut, JA | 1 |
| Michel, G | 1 |
| Tubiana, N | 1 |
| Blaise, D | 1 |
| Novakovitch, G | 2 |
| Rossi, JF | 1 |
| Weiller, PJ | 1 |
| Stryckmans, P | 1 |
| De Witte, T | 1 |
| Bitar, N | 1 |
| Marie, JP | 1 |
| Debusscher, L | 1 |
| Peetermans, M | 1 |
| Andrien, JM | 1 |
| Appelbaum, FR | 1 |
| Buckner, CD | 1 |
| Pico, JL | 1 |
| Hartmann, O | 1 |
| Beaujean, F | 1 |
| Benhamou, E | 1 |
| Mascret, B | 1 |
| Ghalie, R | 1 |
| Kalifa, C | 1 |
| Hayat, M | 1 |
| Case, DC | 1 |
| Porensky, RS | 1 |
| Fanning, JP | 1 |
| Carter, SK | 2 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Schein, PS | 1 |
| O'Connell, MJ | 1 |
| Blom, J | 1 |
| Hubbard, S | 1 |
| Magrath, IT | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| Ziegler, JL | 1 |
| DeVita, VT | 1 |
| Holland, JF | 1 |
| Glidewell, O | 1 |
| Frei, E | 1 |
| Schabel, FM | 1 |
| Goldin, A | 1 |
| Tan, CC | 1 |
| Miké, V | 1 |
| Murphy, ML | 1 |
| Gavosto, F | 1 |
| Cunningham, B | 1 |
| Tan, CT | 1 |
| Lustman-Marechal, J | 1 |
| Sher, NA | 2 |
| Pearson, JW | 3 |
| Chaparas, SD | 3 |
| Chirigos, MA | 3 |
| Aungst, CW | 1 |
| Chirigos, M | 1 |
| Pearson, J | 1 |
| Sher, N | 1 |
| Pryor, J | 1 |
| Fairley, GH | 1 |
| Benvenisti, D | 1 |
| Dollinger, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
6 reviews available for carmustine and Leukemia, Lymphocytic
| Article | Year |
|---|---|
Chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Chromosomes, Human, 6-12 | 1984 |
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1982 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
New cancer chemotherapeutic agents.
Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bl | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosin | 1971 |
9 trials available for carmustine and Leukemia, Lymphocytic
| Article | Year |
|---|---|
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2006 |
Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults.
Topics: Adolescent; Adult; Asparaginase; BCG Vaccine; Carmustine; Child; Child, Preschool; Cyclophosphamide; | 1983 |
Combination chemotherapy study for remission maintenance in ALL: an evaluation of vincristine, cyclophosphamide and vincristine, cyclophosphamide, and BCNU: a Southwest Oncology Group Phase II Study.
Topics: Adolescent; Adult; Carmustine; Child; Cyclophosphamide; Drug Evaluation; Drug Synergism; Drug Therap | 1981 |
Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).
Topics: Adolescent; Allopurinol; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1982 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
Chemotherapy of acute lymphocytic leukemia of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Carmustine; Cell Division; Cell Transformati | 1972 |
30 other studies available for carmustine and Leukemia, Lymphocytic
| Article | Year |
|---|---|
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; CD2 A | 2003 |
Testicular invasion and relapse and meningeal involvement in a rat T-cell leukaemia.
Topics: Animals; Carmustine; Disease Models, Animal; Female; Leukemia, Lymphoid; Male; Meningeal Neoplasms; | 1984 |
Interaction between human lymphoblastoid interferon and chemotherapeutic agents in vitro.
Topics: Antineoplastic Agents; B-Lymphocytes; Carmustine; Cyclophosphamide; Cytarabine; DNA Replication; Dox | 1984 |
Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1984 |
Combination chemotherapy of Rauscher leukemia and ascites tumors by narcissus alkaloid with standard drugs and effect on cellular immunity.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Blood Cells; Carcinoma, Ehrlich Tumor; Carmu | 1975 |
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications.
Topics: Adult; Bone Marrow; Carmustine; Cytarabine; Diploidy; Drug Therapy, Combination; Female; Humans; Leu | 1977 |
L2C leukemia: a model of human acute leukemia.
Topics: Age Factors; Animals; BCG Vaccine; Carmustine; Central Nervous System Diseases; Cerebral Ventricle N | 1977 |
Clinical bone marrow transplantation (BMT) in children with acute lymphoblastic leukemia (ALL). Presentation of cases (Munchen group) [proceedings].
Topics: Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Cytarabine; Female; Graft Survival | 1978 |
Delayed cutaneous hypersensitivity to oxazolone in mice with tumors.
Topics: Animals; Carmustine; Doxorubicin; Female; Hypersensitivity, Delayed; Leukemia, Experimental; Leukemi | 1978 |
Response of transplanted AKR leukemia to combination therapy with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea: dose and schedule dependency.
Topics: Amphotericin B; Animals; Carmustine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1977 |
The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Topics: Alkylating Agents; Animals; Binding, Competitive; Biological Transport; Carmustine; Cell Line; Chlor | 1975 |
Treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Asparaginase; Carmustine; Child; Cytarabine; Daunorubicin; Female; Humans; | 1975 |
Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Brain Neoplasms; Carmustine; Child; Child, Presc | 1976 |
Pancreatic carcinoma as a sequel to therapy of lymphoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Carmustine; Cyclophosphamide; Female; Hodg | 1976 |
A murine model for central nervous system leukemia and its possible relevance to human leukemia.
Topics: Amphotericin B; Animals; Brain; Carmustine; Central Nervous System Diseases; Disease Models, Animal; | 1975 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1988 |
Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmu | 1987 |
Modified chemotherapy with carmustine, cytarabine, cyclophosphamide, and 6-thioguanine (BACT) and autologous bone marrow transplantation in 24 poor-risk patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1986 |
Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; L | 1985 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).
Topics: Administration, Oral; Adolescent; Age Factors; Antineoplastic Agents; Asparaginase; Carmustine; Chem | 1974 |
[Treatment of acute leukemia].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Humans; Leukemia, Lymphoid; Leukemia, Monocytic | 1973 |
Comparative results obtained in the treatment of acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination | 1973 |
[Neuromeningeal irradiation during the treatment of acute lymphoblastic leukemia].
Topics: Acute Disease; Age Factors; Asparaginase; Carmustine; Central Nervous System; Child; Child, Preschoo | 1974 |
Effect of three strains of BCG against a murine leukemia after drug therapy.
Topics: Animals; Antigens, Bacterial; BCG Vaccine; Carmustine; Leukemia, Experimental; Leukemia, Lymphoid; M | 1973 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Combined drug and immunostimulation therapy against a syngeneic murine leukemia.
Topics: Animals; BCG Vaccine; Carmustine; Corynebacterium; Diethylamines; Evaluation Studies as Topic; Fluor | 1974 |
BCG immunization for the lymphoid leukemia line (LSTRA) in CDF1 mice.
Topics: Animals; BCG Vaccine; Carmustine; Cell Line; Dose-Response Relationship, Drug; Leukemia, Experimenta | 1973 |
Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immunoadjuvant.
Topics: Adjuvants, Immunologic; Animals; Carmustine; Graft Rejection; Leukemia, Experimental; Leukemia, Lymp | 1973 |
Experimental studies with L-asparaginase in mouse leukemias.
Topics: Animals; Antibiotics, Antineoplastic; Asparaginase; Asparagine; Carmustine; Cell Line; Child, Presch | 1970 |